Loncar Cancer Immunotherapy Etf Probability of Future Etf Price Finishing Over 13.40
| CNCR Etf | USD 11.97 0.05 0.42% |
Loncar |
Loncar Cancer Target Price Odds to finish over 13.40
The tendency of Loncar Etf price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 13.40 or more in 90 days |
| 11.97 | 90 days | 13.40 | about 88.06 |
Based on a normal probability distribution, the odds of Loncar Cancer to move over $ 13.40 or more in 90 days from now is about 88.06 (This Loncar Cancer Immunotherapy probability density function shows the probability of Loncar Etf to fall within a particular range of prices over 90 days) . Probability of Loncar Cancer Immuno price to stay between its current price of $ 11.97 and $ 13.40 at the end of the 90-day period is about 11.66 .
Given the investment horizon of 90 days the etf has the beta coefficient of 1.54 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Loncar Cancer will likely underperform. Additionally Loncar Cancer Immunotherapy has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Loncar Cancer Price Density |
| Price |
Predictive Modules for Loncar Cancer
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Loncar Cancer Immuno. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Loncar Cancer's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Loncar Cancer Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Loncar Cancer is not an exception. The market had few large corrections towards the Loncar Cancer's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Loncar Cancer Immunotherapy, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Loncar Cancer within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.4 | |
β | Beta against Dow Jones | 1.54 | |
σ | Overall volatility | 0.90 | |
Ir | Information ratio | -0.18 |
Loncar Cancer Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Loncar Cancer for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Loncar Cancer Immuno can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Loncar Cancer Immuno generated a negative expected return over the last 90 days | |
| Latest headline from news.google.com: CSHL and Range ETFs launch new partnership - Cold Spring Harbor Laboratory | |
| Loncar Cancer Immuno created five year return of -11.0% | |
| This fund holds 99.87% of its assets under management (AUM) in equities |
Loncar Cancer Technical Analysis
Loncar Cancer's future price can be derived by breaking down and analyzing its technical indicators over time. Loncar Etf technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Loncar Cancer Immunotherapy. In general, you should focus on analyzing Loncar Etf price patterns and their correlations with different microeconomic environments and drivers.
Loncar Cancer Predictive Forecast Models
Loncar Cancer's time-series forecasting models is one of many Loncar Cancer's etf analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Loncar Cancer's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the etf market movement and maximize returns from investment trading.
Things to note about Loncar Cancer Immuno
Checking the ongoing alerts about Loncar Cancer for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Loncar Cancer Immuno help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Loncar Cancer Immuno generated a negative expected return over the last 90 days | |
| Latest headline from news.google.com: CSHL and Range ETFs launch new partnership - Cold Spring Harbor Laboratory | |
| Loncar Cancer Immuno created five year return of -11.0% | |
| This fund holds 99.87% of its assets under management (AUM) in equities |
Check out Loncar Cancer Backtesting, Portfolio Optimization, Loncar Cancer Correlation, Loncar Cancer Hype Analysis, Loncar Cancer Volatility, Loncar Cancer History as well as Loncar Cancer Performance. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.